Indications and uses
■ Intensive EGF peptide emulsion is formulated with EGF, peptide and collagen for brightening and firming.
■ Intensive EGF peptide emulsion is formulated with EGF, peptide and collagen for brightening and firming.
■ Can be used daily, AM and PM. Gently massage onto face in circular motions untill absorbed.
NIACINAMIDE 2.0%
ADENOSINE 0.04%
Water(Aqua), Butylene glycol, Butylene Glycol Dicaprylate/Dicaprate, Helianthus Annuus (Sunflower) Seed Oil, 1,2-Hexanediol, Glyceryl Stearate,
Arachidyl Alcohol, Cyclopentasiloxane, Polysorbate 60, Phenoxyethanol, Dimethicone, Diisostearyl Malate, Behenyl Alcohol, Cyclohexasiloxane, PEG-100 Stearate, Arachidyl Glucoside, Sorbitan Stearate, Hydrogenated Lecithin, Xanthan GUM, Tocopheryl Acetate, Allantoin, Carbomer, Ethylhexylglycerin, Disodium EDTA, Arginine, Sodium Hyaluronate, Parfum, Glycerin, Glucose, Tocopherol, Thymus Vulgaris (Thyme) Extract, Phaseolus Radiatus Meristem Cell Culture Extract, Panax ginseng culture extract, Camellia sinensis Callus Culture extracts, Malva Sylvestris (Mallow) Flower Extract, Buddleja Davidii Extract, Myrciaria Dubia Fruit Extract, Euterpe Oleracea Fruit Extract, Sodium Benzoate, Potassium Sorbate, Hydrolyzed Collagen, Citric Acid, Caprylyl Glycol, Punica Granatum Fruit Extract, Panax Ginseng Root Extract, Carthamus Tinctorius (Safflower) Flower Extract, Acanthopanax Senticosus (Eleuthero) Root Extract, Solanum Lycopersicum (Tomato) Fruit Extract,
Nelumbo Nucifera Seed Extract, Lonicera Japonica (Honeysuckle) Flower Extract, Lilium Tigrinum Extract, Chrysanthemum Indicum Flower Extract, Tropolone, Copper Tripeptide-1, Oligopeptide-1
Skin Brightening
Anti wrinkle
For external use only.
Avoid contact with eyes.
Keep out of reach of children.
Discontinue use if signs of irritation appear.
Keep out of reach of children
■ Intensive EGF peptide emulsion is formulated with EGF, peptide and collagen for brightening and firming.
■ Can be used daily, AM and PM. Gently massage onto face in circular motions untill absorbed.
| Class | Version | Type | Effective |
|---|---|---|---|
| ADENOSINE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| d676a241-be05-4740-b3ee-1a5f2ed422d2 | Product name | 4 | 20180615 |
| dd8bd48f-20d6-43c7-b471-3ae872868afa | Product name | 3 | 20180125 |
| d41954ff-bc63-4b2c-aba0-9146707659d7 | Product name | 2 | 20151117 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 73590-0072-1 | COXIR INTENSIVE EGF PEPTIDE | 100 mL in 1 CONTAINER | EMULSION | 100 | 1 | |
| 73590-0072-2 | COXIR INTENSIVE EGF PEPTIDE | 1 in 1 CARTON | EMULSION | 1 | 1 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 73590-0072 | COXIR INTENSIVE EGF PEPTIDE (NIACINAMIDE, ADENOSINE) EMULSION [NOKSIBCHO COSMETIC CO., LTD.] | 1 | Current NDC, Legacy NDC, 2 package rows | 20210715_2f121591-4c13-4824-95d6-bd3ab4ee17c9.zip |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 73590-0072 | 73590-0072-1, 73590-0072-2 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| NIACINAMIDE | 25X51I8RD4 | ACTIB |
| ADENOSINE | K72T3FS567 | ACTIB |
| Water | 059QF0KO0R | IACT |
| Butylene Glycol | 3XUS85K0RA | IACT |
| BUTYLENE GLYCOL DICAPRYLATE/DICAPRATE | 75D21FL1PI | IACT |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| COXIR INTENSIVE EGF PEPTIDE | NIACINAMIDE, ADENOSINE | NOKSIBCHO cosmetic Co., Ltd. | 2f121591-4c13-4824-95d6-bd3ab4ee17c9 | 2021-07-14 | Warnings | 73590-0072-1 73590-0072-2 73590-0072 73590007202 73590007201 9f3c92eb-5820-46c6-bcc6-109ef6e0f60b 2f121591-4c13-4824-95d6-bd3ab4ee17c9 |
Adverse event summaries are temporarily unavailable. Other product information remains available.